Drug Trial Radar · NCT07743164
A Clinical Trial of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab in Participants With Ovarian Cancer Who Have Progressed During Treatment With PARP-inhibitors Treatment on First Line Maintenance (MK-5909-008/ENGOT-ov107/GOG-3142 / REJOICE-Ovarian05)
Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
646
Planned (sponsor's estimate)
Start
Oct 7, 2026
Primary completion
Aug 31, 2031
Study completion Aug 31, 2031
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- Collaborators
- Daiichi Sankyo
- First posted
- Aug 3, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Researchers are looking for new ways to treat advanced, high-grade ovarian cancer (OC). Advanced means the cancer has spread to other parts of the body (metastatic) and may not be removed with surgery. High-grade means the cancer cells grow and spread quickly. This trial includes types of OC that started in cells that cover the ovaries, in the lining of the belly, or in the fallopian tubes. The usual treatment for high-grade OC may include one or both of these: * Chemotherapy, which is a treatment that uses medicine to destroy cancer cells or stop them from growing. * Bevacizumab, which is a targeted therapy that works to control how specific types of cancer cells grow and spread and targets tumor blood vessels. Researchers want to learn about the trial medicine, raludotatug deruxtecan (also called R-DXd or MK-5909), when given with and without bevacizumab and how participants respond to it. R-DXd is an antibody drug conjugate (ADC). An ADC is a type of medicine that attaches to a specific target on cancer cells and delivers treatment to destroy those cells. The goals of this trial are to learn if participants who receive R-DXd, with or without bevacizumab, live longer overall and without their cancer growing or spreading compared to those who receive usual treatment.
Conditions
- Ovarian Cancer
- Peritoneal Cancer
- Fallopian Tube Cancer
Interventions
R-DXdBiological
R-DXd alone or in combination with bevacizumab administered via IV infusion
BevacizumabDrug
Bevacizumab 10 or 15 mg/kg administered via IV infusion on day 1 q3w
CarboplatinDrug
Carboplatin area under the curve (AUC) 5 mg/mL\*min or AUC 4 mg/mL\*min administered on day 1 q3w for a maximum of 8 cycles
PaclitaxelDrug
Paclitaxel 175 mg/m\^2 administered via IV infusion on day 1 q3w for a maximum of 8 cycles
GemcitabineDrug
Gemcitabine 1000 mg/mL administered via IV infusion on day 1 and day 8 of each 3-week cycle for a maximum of 8 cycles
Pegylated liposomal doxorubicin (PLD)Drug
PLD 30 mg/m\^2 administered via IV infusion on day 1 of each 4-week cycles for a maximum of 8 cycles
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free Survival (PFS)Time frame: Up to approximately 3 years
- Overall Survival (OS)Time frame: Up to approximately 4 years
Locations
9 sites in 5 countries. Site status is shown where the registry gives one.
MemorialCare Orange Coast Medical Center ( Site 0032)
Fountain Valley, California · Recruiting
Orlando Health Cancer Institute ( Site 0018)
Orlando, Florida · Recruiting
Lahey Clinic ( Site 0042)
Burlington, Massachusetts · Recruiting
JPS Oncology and Infusion Center ( Site 0019)
Fort Worth, Texas · Recruiting
Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology ( Site 9000)
Wuhan, Hubei, China · Recruiting
Hadassah Medical Center ( Site 2700)
Jerusalem, Israel · Recruiting
Sourasky Medical Center ( Site 2701)
Tel Aviv, Israel · Recruiting
Seoul National University Hospital ( Site 5202)
Seoul, South Korea · Recruiting
National Cheng Kung University Hospital ( Site 5304)
Tainan, Taiwan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.